Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4266078 | Transplantation Reviews | 2012 | 8 Pages |
Abstract
Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) formulation, has improved both short- and long-term outcomes following renal transplantation, but is often associated with gastrointestinal (GI) complications that can lead to dose reduction or discontinuation, potentially jeopardizing patient outcomes. Enteric-coated mycophenolate sodium (EC-MPS) delivers equivalent MPA exposure to MMF and offers the potential to reduce GI burden (while maintaining patient safety). Here we review the efficacy of EC-MPS compared with MMF in renal transplant patients in terms of biopsy-proven acute rejection and graft loss, and examine the use of EC-MPS in newer regimens such as intensified dosing and calcineurin inhibitor minimization.
Related Topics
Health Sciences
Medicine and Dentistry
Transplantation
Authors
Matthew Cooper, Maurizio Salvadori, Klemens Budde, Frederic Oppenheimer, Hans Sollinger, Martin Zeier,